Maxion Therapeutics

To add a bio or update company history, please click update information.

News from Maxion Therapeutics

Maxion Therapeutics raises £58m in Series A led by General Catalyst to advance KnotBody pipeline

17 Mar 2025

Maxion Therapeutics raises £58m in Series A led by General Catalyst to advance KnotBody pipeline

Maxion Therapeutics develops antibody-based KnotBody drugs targeting ion channels and GPCRs, advancing new treatments for inflammatory, pain and cardiovascular diseases with improved selectivity.

Maxion Therapeutics

Life Sciences
Cambridge, United Kingdom
£58m
maxiontherapeutics.com
Update Information

More venture news

Sequential Bio
17 Mar 2026
Sequential secures £2.6m in funding led by Sparkfood and Corundum Systems Biology for non-invasive testing of skin health ingredients
EquityLife Sciences
Ternary Therapeutics
16 Mar 2026
Ternary Therapeutics raises a £3.6m seed round led by daphni to engineer molecular glue medicines
SeedLife Sciences
BIOCAPTIVA
9 Mar 2026
BIOCAPTIVA secures £1.6m in funding led by Archangels for magnetic bead tech that prepares blood samples for liquid biopsy
EquityLife Sciences

Maxion Therapeutics

News from Maxion Therapeutics

Maxion Therapeutics raises £58m in Series A led by General Catalyst to advance KnotBody pipeline

More venture news

Sequential secures £2.6m in funding led by Sparkfood and Corundum Systems Biology for non-invasive testing of skin health ingredients

Ternary Therapeutics raises a £3.6m seed round led by daphni to engineer molecular glue medicines

BIOCAPTIVA secures £1.6m in funding led by Archangels for magnetic bead tech that prepares blood samples for liquid biopsy